- Home
- ARCT vs PMI Comparison
ARCT vs PMI Comparison
Compare ARCT & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- PMI
- Stock Information
- Founded
- ARCT 2013
- PMI 1981
- Country
- ARCT United States
- PMI United States
- Employees
- ARCT N/A
- PMI N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- PMI
- Sector
- ARCT Health Care
- PMI
- Exchange
- ARCT Nasdaq
- PMI Nasdaq
- Market Cap
- ARCT 526.5M
- PMI 605.1M
- IPO Year
- ARCT N/A
- PMI 2025
- Fundamental
- Price
- ARCT $10.59
- PMI $4.75
- Analyst Decision
- ARCT Buy
- PMI
- Analyst Count
- ARCT 10
- PMI 0
- Target Price
- ARCT $35.25
- PMI N/A
- AVG Volume (30 Days)
- ARCT 2.1M
- PMI 3.3M
- Earning Date
- ARCT 11-07-2025
- PMI 12-16-2025
- Dividend Yield
- ARCT N/A
- PMI N/A
- EPS Growth
- ARCT N/A
- PMI N/A
- EPS
- ARCT N/A
- PMI N/A
- Revenue
- ARCT $122,122,000.00
- PMI $4,461,000.00
- Revenue This Year
- ARCT N/A
- PMI N/A
- Revenue Next Year
- ARCT $34.32
- PMI N/A
- P/E Ratio
- ARCT N/A
- PMI N/A
- Revenue Growth
- ARCT N/A
- PMI 1.36
- 52 Week Low
- ARCT $8.04
- PMI $3.25
- 52 Week High
- ARCT $24.17
- PMI $13.68
- Technical
- Relative Strength Index (RSI)
- ARCT 31.16
- PMI N/A
- Support Level
- ARCT $9.19
- PMI N/A
- Resistance Level
- ARCT $12.10
- PMI N/A
- Average True Range (ATR)
- ARCT 1.78
- PMI 0.00
- MACD
- ARCT -1.35
- PMI 0.00
- Stochastic Oscillator
- ARCT 9.36
- PMI 0.00
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.